More Ups Than Downs In Latest Drug Price Adjustment
This article was originally published in PharmAsia News
China's National Development and Reform Commission (NDRC) recently adjusted the price of 47 formulations for 26 types of generic drugs, including Mycetozoan and Rifampicin. While the previous 24 adjustments focused on lowering prices, the latest round raised the price of most drugs, up to six-fold. Analysts note that this adjustment will benefit industry development and protect the interests of local manufacturers producing cheap medicines with good quality. It could also indicate a new trend of drug price adjustment. However, others caution against relying on a single instance as a reflection of future policy. (Click here for more)
You may also be interested in...
Procter & Gamble, through its UK wellness subsidiary Nature's Best, is on-trend with new vegan vitamin D3 and iron supplements. Nature's Best has also launched three other vitamin D3 products in the country, as well as an ashwagandha supplement.
The MHRA has updated its guidance on regulatory flexibilities for medical devices and medicinal products resulting from COVID-19 to highlight how its approach differs from the EU.
The Swiss company is planning a US trial of CBSO, the first transcatheter septal occluder with a bioresorbable, metal-free frame.